Brokerages Set Avantor, Inc. (NYSE:AVTR) Price Target at $26.29

Avantor, Inc. (NYSE:AVTR) has earned an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $26.29.

AVTR has been the topic of a number of analyst reports. Evercore ISI lowered their price objective on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Barclays lowered their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. Deutsche Bank Aktiengesellschaft raised their target price on Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a report on Thursday, April 18th. Finally, Robert W. Baird lowered their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th.

Avantor Stock Performance

Shares of AVTR stock opened at $20.94 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.61 and a quick ratio of 1.05. The firm has a market cap of $14.22 billion, a P/E ratio of 53.69, a PEG ratio of 2.13 and a beta of 1.32. The stock’s 50-day moving average is $23.26 and its two-hundred day moving average is $23.74. Avantor has a fifty-two week low of $16.63 and a fifty-two week high of $26.16.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Friday, April 26th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. The business had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.68 billion. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 EPS. Analysts predict that Avantor will post 1.01 earnings per share for the current fiscal year.

Institutional Trading of Avantor

Large investors have recently made changes to their positions in the business. Mesirow Institutional Investment Management Inc. acquired a new stake in Avantor in the 4th quarter valued at about $2,842,000. Raymond James & Associates raised its position in Avantor by 84.8% in the 4th quarter. Raymond James & Associates now owns 1,165,646 shares of the company’s stock worth $26,612,000 after purchasing an additional 534,901 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Avantor by 19.9% during the 4th quarter. Federated Hermes Inc. now owns 628,189 shares of the company’s stock worth $14,342,000 after buying an additional 104,296 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Avantor by 146.1% in the 4th quarter. BNP Paribas Financial Markets now owns 217,296 shares of the company’s stock valued at $4,961,000 after buying an additional 129,010 shares during the last quarter. Finally, DAVENPORT & Co LLC increased its stake in shares of Avantor by 17.6% in the 4th quarter. DAVENPORT & Co LLC now owns 2,283,767 shares of the company’s stock valued at $52,430,000 after buying an additional 342,452 shares during the period. Institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.